Hepatic encephalopathy in alcoholic cirrhosis

Handbook of Clinical Neurology

Volumn 125, Issue , 2014, Pages 589-602

  Butterworth, Roger F ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Alzheimer type II astrocytes; Ammonia; Cirrhosis; Dopamine; GABA; Hepatic coma; Hepatic encephalopathy; Magnetic resonance imaging; Manganese; Neurosteroids; Neurotransmitters; Serotonin

Indexed keywords

ALCOHOLISM; ANIMAL; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS, ALCOHOLIC; METABOLISM;

ALCOHOLISM; ANIMALS; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER CIRRHOSIS, ALCOHOLIC;

EID: 84907983350     PISSN: 00729752     EISSN: 22124152     Source Type: Book Series    
DOI: 10.1016/B978-0-444-62619-6.00034-3     Document Type: Chapter

References (105)

1. Agrawal A., Sharma B.C., Sharma P., et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomised controlled trial of lactulose, probiotics and no therapy. Am J Gastroenterol 2012, 107(7):1043-1050.
2. Ahboucha S., Pomier-Layrargues G., Mamer O., et al. Increased brain concentrations of a neuroinhibitory steroid in human hepatic encephalopathy. Ann Neurol 2005, 58:169-170.
3. Bajaj J.S., Saeian K. MELD score does not discriminate against patients with hepatic encephalopathy. Dig Dis Sci 2005, 50:753-756.
4. Bajaj J.S., Hafeezullah M., Hoffman R.G., et al. Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am J Gastroenterol 2007, 102:1903-1909.
5. Bajaj J.S., Hafeezullah M., Franco J., et al. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology 2008, 135:1591-1600.
6. Bajaj J.S., Wade J.B., Sanyal A.J. Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology 2009, 50:2014-2021.
7. Bajaj J.S., Schubert C.M., Heuman D.M., et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology 2010, 138:2332-2340.
8. Bass N.M., Mullen K.D., Sanyal A., et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010, 362:1071-1081.
9. 31P nuclear magnetic resonance study. J Neurochem 1989, 53:102-110.
10. Bélanger M., Ahboucha S., Desjardins P., et al. Upregulation of peripheral-type (mitochondrial) benzodiazepine receptors in hyperammonemic syndromes: consequences for neuronal excitability. Advances in Molecular and Cell Biology 2004, 31(3):983-997.
11. Bengtsson F., Bugge M., Johansen K.H., et al. Brain tryptophan hydroxylation in the portacaval shunted rat: a hypothesis for the regulation of serotonin turnover in vivo. J Neurochem 1991, 56:1069-1074.
12. Bergeron M., Reader T.A., Pomier Layrargues G., et al. Monoamines and metabolites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Neurochem Res 1989, 14:853-859.
13. Bergeron M., Swain M.S., Reader T.A., et al. Effect of ammonia on brain serotonin metabolism in relation to function in the portacaval shunted rat. J Neurochem 1990, 55:222-229.
14. Burkhard P.R., Delavelle J., Du Pasquier R., et al. Chronic parkinsonism associated with cirrhosis: a distinct subset of acquired hepatocerebral degeneration. Arch Neurol 2003, 60:521-528.
15. Butterworth R.F. Neuronal cell death in hepatic encephalopathy. Metab Brain Dis 2007, 22:309-320.
16. Butterworth R.F. Parkinsonism in cirrhosis: pathogenesis and current therapeutic options. Metab Brain Dis 2013, 28:261-267.
17. Butterworth R.F., Giguère J.F. Cerebral amino acids in portal-systemic encephalopathy: lack of evidence for altered γ-aminobutyric acid (GABA) function. Metab Brain Dis 1986, 1:221-228.
18. Butterworth R.F., Heroux M. Effect of pyrithiamine treatment and subsequent thiamine rehabilitation on regional cerebral amino acids and thiamine-dependent enzymes. J Neurochem 1989, 52:1079-1084.
19. Butterworth R.F., Giguère J.F., Michaud J., et al. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol 1987, 6:1-12.
20. 3H-muscimol (GABA-A) binding sites and central benzodiazepine receptors are unchanged in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Hepatology 1988, 8:1084-1088.
21. Butterworth R.F., Tonon M.C., Désy L., et al. Increased brain content of the endogenous benzodiazepine receptor ligand octadecaneuropeptide (ODN) following portacaval anastomosis in the rat. Peptides 1991, 12:119-125.
22. Butterworth R.F., Wells J., Pomier Layrargues G. Detection of benzodiazepines in hepatic encephalopathy. Reply. Hepatology 1995, 21:605.
23. Cagnin A., Taylor-Robinson S.D., Forton D.M., et al. In vivo imaging of cerebral peripheral benzodiazepine binding sites in patients with hepatic encephalopathy. Gut 2006, 55:547-553.
24. Chatauret N., Butterworth R.F. Effects of liver failure on inter-organ trafficking of ammonia: implications for the treatment of encephalopathy. J Gastroenterol Hepatol 2004, 19:S219-S223.
25. Ciancio A., Marchet A., Saracco G., et al. Spectral electroencephalogram analysis in hepatic encephalopathy and liver transplantation. Liver Transpl 2002, 8:630-635.
26. Cordoba J. New assessment of hepatic encephalopathy. J Hepatol 2011, 54:1030-1040.
27. Cordoba J., Cabrera J., Lataif L., et al. High prevalence of sleep disturbance in cirrhosis. Hepatology 1998, 27(2):339-345.
28. Cordoba J., López-Hellín J., Planas M., et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004, 41:38-43.
29. Desjardins P., Rama Rao V.K., et al. Effect of portacaval anastomosis on glutamine synthetase protein and gene expression in brain, liver and skeletal muscle. Metab Brain Dis 1999, 14:273-282.
30. Devenyi A.G., Barron T.F., Mamourian A.C. Dystonia, hyperintense basal ganglia, and high whole blood manganese levels in Alagilles's syndrome. Gastroenterology 1994, 106:1068-1071.
31. Dhiman R.K., Kurmi R., Thumburu K.K., et al. Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver. Dig Dis Sci 2010, 55:2381-2390.
32. Felipo V., Butterworth R.F. Neurobiology of Ammonia. Prog Neurobiol 2002, 67:259-279.
33. Gabuzda G., Philips G.B., Davidson C.S. Reversible toxic manifestations in patients with cirrhosis of the liver given cation-exchange resins. N Engl J Med 1952, 246:124-130.
34. Ganda O.P., Ruderman N.B. Muscle nitrogen metabolism in chronic hepatic insufficiency. Metabolism 1976, 25(4):427-435.
35. Gyr K., Meier R., Haussler J., et al. Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomised, placebo controlled multicentre study. Gut 1996, 39:319-324.
36. Hindfelt B., Plum F., Duffy T.E. Effects of acute ammonia intoxication on cerebral metabolism in rats with portacaval shunts. J Clin Invest 1977, 59:386-396.
37. Jacobs E.H., Yamatodani A., Timmerman H. Is histamine the final neurotransmitter in the entrainment of circadian rhythms in mammals?. Trends Pharmacol Sci 2000, 21:293-298.
38. 13N-ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography. Hepatology 2006, 43:42-50.
39. Kircheis G., Nilius R., Held C., et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997, 25(6):1351-1360.
40. Kircheis G., Wettstein M., Timmermann L., et al. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002, 35:357-366.
41. Kril J.J., Butterworth R.F. Diencephalic and cerebellar pathology in alcoholic and non-alcoholic patients with end-stage liver disease. Hepatology 1997, 26:837-841.
42. Lai J.C.K., Cooper A.J.L. Brain α-ketoglutarate dehydrogenase: kinetic properties, regional distribution and effects of inhibitors. J Neurochem 1986, 47:1376-1386.
43. Laubenberger J., Haussinger D., Boyer S., et al. Proton magnetic resonance spectroscopy of brain in symptomatic and asymptomatic patients with liver cirrhosis. Gastroenterology 1997, 112:1610-1616.
44. Lavoie J., Giguère J.F., Pomier Layrargues G., et al. Amino acid changes in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. J Neurochem 1987, 49:692-697.
45. Lavoie J., Pomier Layrargues G., Butterworth R.F. Increased densities of "peripheral-type" benzodiazepine receptors in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Hepatology 1990, 11:874-878.
46. Lockwood A.H., Yap E.W.H., Wong W.-H. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 1991, 11:337-341.
47. Lockwood A.H., Weissenborn K., Butterworth R.F. An image of the brain in patients with liver disease. Curr Opin Neurol 1997, 10:525-533.
48. Lockwood A.H., Weissenborn K., Bokemeyer M., et al. Correlations between cerebral glucose metabolism and neuropsychological test performance in non-alcoholic cirrhotics. Metab Brain Dis 2002, 17:29-40.
49. Lozeva V., Valjakka A., Lecklin A., et al. Effects of the histamine H(1) receptor blocker, pyrilamine, on spontaneous locomotor activity of rats with long-term portacaval anastomosis. Hepatology 2000, 31(2):336-344.
50. Lozeva V., Montgomery J.A., Tuomisto L., et al. Increased brain serotonin turnover correlates with the degree of shunting and hyperammonemia in rats following variable portal vein stenosis. J Hepatol 2004, 40:742-748.
51. Lozeva-Thomas V., Ahonen P., Chatauret N., et al. Brain histamine in experimental acute liver failure: effects of L-histidine loading. Inflamm Res 2004, 53(Suppl. 1):S55-S56.
52. Malaguarnera M., Pistone G., Elvira R., et al. Effects of L-carnitine in patients with hepatic encephalopathy. World J Gastroenterol 2005, 11(45):7197-7202.
53. Mattarozzi K., Stracciari A., Vignatelli L., et al. Minimal hepatic encephalopathy: longitudinal effects of liver transplantation. Arch Neurol 2004, 61:242-247.
54. Michel H., Solere M., Granier P., et al. Treatment of cirrhotic hepatic encephalopathy with L-DOPA. A controlled trial. Gastroenterology 1980, 29:555-561.
55. 1-weighted MR images in patients receiving parenteral nutrition. Radiology 1991, 191:117-120.
56. Morgan M.Y., Jakobovits A.W., James I.M., et al. Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy. Gastroenterology 1980, 78:663-670.
57. Mousseau D.D., Perney P., Pomier Layrargues G., et al. Selective loss of pallidal dopamine D2 receptor density in hepatic encephalopathy. Neurosci Lett 1993, 162:192-196.
58. Mousseau D.D., Baker G.B., Butterworth R.F. Increased density of catalytic sites and expression of brain monoamine oxidase A in humans with hepatic encephalopathy. J Neurochem 1997, 68:1200-1208.
59. Mullen K.D., Prakash R.K. Antibiotic treatment for hepatic encephalopathy. Hepatic Encephalopathy 2012, 159-164. Humana Press/Springer, New York. K.V. Mullen, R.V. Prakash (Eds.).
60. Mullen K.D., Szauter K.M., Kaminsky-Russ K. "Endogenous" benzodiazepine activity in body fluids of patients with hepatic encephalopathy. Lancet 1990, 336:81-83.
61. Navarro D., Zwingmann C., Chatauret N., et al. Glucose loading precipitates focal lactic acidosis in vulnerable medial thalamus of thiamine-deficient rats. Metab Brain Dis 2008, 23:115-122.
62. Norenberg M.D. The role of astrocytes in hepatic encephalopathy. Neurochem Pathol 1987, 6:13-33.
63. Norenberg M.D., Lapham L.W. The astrocyte response in experimental portal-systemic encephalopathy: an electron microscope study. J Neuropathol Exp Neurol 1974, 33:422-435.
64. Odeh M. Pathogenesis of hepatic encephalopathy: the tumour necrosis factor-alpha theory. Eur. J Clin Invest 2007, 37:291-304.
65. Odeh M., Sabo E., Srugo I., et al. Relationship between tumour necrosis factor-alpha and ammonia in patients with hepatic encephalopathy due to chronic liver failure. Ann Med 2005, 37:603-612.
66. Olasmaa M., Rothstein J.D., Guidotti A., et al. Endogenous benzodiazepine receptor ligands in human and animal hepatic encephalopathy. J Neurochem 1990, 55:2015-2023.
67. Plauth M., Cabré E., Riggio O., et al. ESPEN Guidelines on enteral nutrition in liver disease. Clin Nutr 2006, 25:285-294.
68. Pomier-Layrargues G. TIPS and hepatic encephalopathy. Semin Liver Dis 1996, 16:315-320.
69. Pomier-Layrargues G., Giguère J.F., Lavoie J., et al. Clinical efficacy of benzodiazepine antagonist RO 15-1788 (flumazenil) in cirrhotic patients with hepatic coma: results of a randomized double-blind placebo-controlled cross-over trial. Hepatology 1994, 19:32-37.
70. Pomier-Layrargues G., Spahr L., Butterworth R.F. Increased manganese concentrations magnetic resonance hyperintensity?. Lancet 1995, 345:735.
71. Prasad S., Dhiman R.K., Duseja A., et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007, 45:549-559.
72. Pujol J., Kulisevsky J., Moreno A., et al. Neurospectroscopic alterations and globus pallidus hyperintensity as related magnetic resonance markers of reversible hepatic encephalopathy. Neurology 1996, 47:1526-1530.
73. Raabe W. Synaptic transmission in ammonia intoxication. Neurochem Pathol 1987, 6:145-166.
74. 3H]-ketanserin binding sites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Neurosci Lett 1994, 182:69-72.
75. Randolph C., Hilsabeck R., Kato A., et al. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int 2009, 29:629-635.
76. Riggio O., Ridola L., Pasquale C., et al. Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy. Clin Gastroenterol Hepatol 2011, 9:181-183.
77. Romero-Gomez M., Córdoba J., Jover R., et al. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology 2007, 45:879-885.
78. Rose C., Michalak A., Pannunzio P., et al. L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action. Metab Brain Dis 1998, 13(2):24-32.
79. Rose C., Butterworth R.F., Zayed J., et al. Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. Gastroenterology 1999, 117:640-644.
80. Rossle M., Euringer W. Hepatic encephalopathy in patients with transjugular intrahepatic portosystemic shunt (TIPS). Hepatic encephalopathy: Clinical Gastroenterology 2012, 211-220. Humana Press/Springer, New York. K.D. Mullen, R.K. Prakash (Eds.).
81. Rothstein J.D., McKhann G., Guarneri P., et al. Hepatic encephalopathy and cerebrospinal fluid content of diazepam binding inhibitor (DBI). Ann Neurol 1989, 26:57-62.
82. Roy S., Pomier-Layrargues G., Butterworth R.F., et al. Hepatic encephalopathy in cirrhotic and portacaval shunted dogs: lack of changes in brain GABA uptake, brain GABA levels, brain glutamic acid decarboxylase and brain postsynaptic GABA receptors. Hepatology 1988, 8:845-849.
83. Schafer D.F., Jones E.A. Hepatic encephalopathy and the γ-aminobutyric acid system. Lancet 1982, 1:18-20.
84. Schleiss F., Gorg B., Fischer R., et al. Ammonia induces MK-801 sensitive nitration and phosphopylation of protein tyrosine residues in rat astrocytes. FASEB J 2002, 16:739-741.
85. Senzolo M., Pizzolato G., Ferronato C., et al. Long term evaluation of cognitive function and cerebral metabolism in liver transplanted patients. Transplant Proc 2009, 41:1295-1296.
86. Sharma B.C., Sharma P., Agrawal A., et al. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009, 137:885-891.
87. Shawcross D.L., Wright G., Olde Daminck S.W.M., et al. Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis 2007, 22:125-138.
88. Shiraishi T., Black K.L., Ikesaki K. Peripheral benzodiazepine receptor ligands induce morphological changes in mitochondria of cultured glioma cells. Soc Neurosci Abs 1990, 16:214-216.
89. Smith J.M., Misiak H. Critical flicker frequency (CFF) and psychotropic drugs in normal human subjects - a review. Psychopharmacologia 1976, 47(2):175-182.
90. Sotil E.U., Gottstein J., Ayala E., et al. Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation. Liver Transpl 2009, 15(2):184-192.
91. Spahr L., Butterworth R.F., Fontaine S., et al. Increased blood manganese in cirrhotic patients: relationship to pallidal magnetic resonance signal hyperintensity and neurological symptoms. Hepatology 1996, 24:1116-1120.
92. 1 blocker Hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized controlled pilot trial. Am J Gastroenterol 2007, 102:744-753.
93. Sushma S., Dasarathy S., Tandon R.K., et al. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 1992, 16(1):138-144.
94. Tarter R.E., Switala J., Plail J., et al. Severity of hepatic encephalopathy before liver transplantation is associated with quality of life after transplantation. Arch Intern Med 1992, 152:2097-2101.
95. Tasaka K. New advances in histamine research 1994, Spinger Verlag, Tokyo.
96. Therrien G., Giguère J.F., Butterworth R.F. Increased cerebrospinal fluid lactate reflects deterioration of neurological status in experimental portal-systemic encephalopathy. Metab Brain Dis 1991, 6:225-231.
97. Therrien G., Butterworth J., Rose C., et al. Protective effect of L-carnitine in ammonia-precipitated encephalopathy in portacaval shunted rats: evidence for a central mechanism of action. Hepatology 1997, 25:551-556.
98. Tofteng F., Jorgensen L., Hansen B.A., et al. Cerebral microdialysis in patients with fulminant hepatic failure. Hepatology 2002, 36:1333-1340.
99. Uribe M., Farca A., Marquez M.A., et al. Treatment of chronic portal-systemic encephalopathy with bromocriptine: a double-blind controlled trial. Gastroenterology 1979, 76:1347-1351.
100. Weissenborn K. Diagnosis of overt hepatic encephalopathy. Hepatic Encephalopathy: Clinical Gastroenterology 2012, 97-102. Humana Press/Springer, New York. K.D. Mullen, R.K. Prakash (Eds.).
101. Weissenborn K., Berding G., Kostler H. Altered striatal dopamine D2 receptor density and dopamine transport in a patient with hepatic encephalopathy. Metab Brain Dis 2000, 15:173-178.
102. Weissenborn K., Ennen J.C., Schomerus H., et al. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001, 34:768-773.
103. Yao H., Sadoshima S., Fujii K., et al. Cerebrospinal fluid lactate in patients with hepatic encephalopathy. Eur Neurol 1987, 27:182-187.
104. Young S.N., Lal S., Feldmuller F., et al. Relationships between tryptophan in serum and CSF and 5-hydroxyindoleacetic acid in CSF of man: effects of cirrhosis of the liver and probenecid administration. J Neurol Neurosurg Psychiatry 1975, 38:322-330.
105. Zemtsova I., Gorg B., Keitel V., et al. Microglial activation in hepatic encephalopathy in rats and humans. Hepatology 2011, 54:204-215.